RxDoctor Payments Data

Page Salenger, MD

Nephrology · Loudonville, NYNPI 1295737609

Payments from drug & device makers

$1,912in general payments, 2019–2025

Across 62 payments — averaging $30.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$185
  • Akebia Therapeutics Inc$175
  • Calliditas Therapeutics US Inc.$172
  • Amgen$168
  • Mallinckrodt Hospital Products Inc.$161
  • Vantive US Healthcare LLC$123
  • plus $927 from 21 others

What the payments were for

  • Food & beverage$1,912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,912 in reported general payments places this provider in the 60th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$130,514
Medicare patients
243
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,940
JardianceEmpagliflozin14$8,920
Sevelamer Carbonate37$4,982
Bumetanide20$492
Torsemide20$346
Gabapentin22$254
Metoprolol Succinate14$249
Atorvastatin Calcium29$204
Losartan Potassium17$194
Pantoprazole Sodium18$187
Lisinopril33$181
Rosuvastatin Calcium11$173
Levothyroxine Sodium15$170
Furosemide57$167
Omeprazole14$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$61$8,94014 claims
Boehringer IngelheimJardiance$98$8,92014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 935 nephrology providers in New York.

Other nephrology in Loudonville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →